Training Hematology and Oncology Fellows in Clinical Research

描述（由申请人提供）：俄亥俄州立大学（OSU）博士后临床T32培训项目的目标是：“血液学和肿瘤学临床研究人员培训”，旨在为血液学和肿瘤学博士后提供最先进的临床研究培训经验，这些博士后拥有医学博士、博士或同等学位，并且坚定地致力于以患者为导向的癌症研究。该培训计划的首要目标是为俄勒冈州立大学血液学和医学肿瘤学部门的血液学和肿瘤学研究员在临床和转化癌症研究方面的学术生涯做好准备。该培训计划的基本原理是基于我们坚定的信念，即癌症治疗和预防的进步将需要强有力的合作努力，以患者为导向的医师研究人员将为实现这一目标提供与医师科学家和基础科学家的关键联系。俄勒冈州立大学综合癌症中心（OSU CCC）提供了丰富的研究环境，促进了多学科之间的合作，但目前缺乏对主要从事以患者为导向的癌症研究的医生有针对性的指导经验。最近科学发现的爆炸性增长和癌症临床试验的日益复杂，特别是新治疗药物和方案的I/II期研究，使得血液学和肿瘤学的学员必须获得适当的指导和培训，为他们在临床和转化研究方面的职业生涯做好准备。该项目认识到，奖学金受训者成功地为富有成效的学术生涯做好准备取决于许多因素，包括智力严谨的课程、资深教师的充分指导和支持、奖学金期间有充足的学术培训时间、开发和撰写临床研究和研究论文的“实践”经验、并有足够的机会通过NCI或其他专业学术组织（如ASCO和ASH）赞助的校外项目和研讨会来提高他们在俄勒冈州立大学的经验。参与的成员包括项目主任、协调委员会成员、咨询委员会成员、主要导师，以及根据他们之前成功指导的记录以及他们对临床和转化研究的承诺而选择的贡献教员。该项目计划为期两年，将重点关注俄勒冈州立大学癌症中心的优势，主要是在癌症预防和实验治疗领域。它的目的是促进和确保奖学金学员的发展，他们将做好充分的准备，不仅在毕业时担任教职人员，而且将被授权成为独立的临床和转化研究人员。此外，俄勒冈州立大学坚定地致力于为学术事业培训女性和未被充分代表的种族和族裔群体成员，该项目将建立在我们在招聘和培训女性和未被充分代表的少数民族研究员方面取得的成功的基础上。

DESCRIPTION (provided by applicant): The objective of this proposed Ohio State University (OSU) postdoctoral clinical T32 training program entitled: "Training Hematology and Oncology Fellows in Clinical Research" is to provide a state of the art clinical research training experienc specifically for postdoctoral fellows in hematology and oncology with an M.D., D.O. or equivalent degree who have demonstrated a firm commitment to patient oriented cancer research. The overriding goal of this training program is to prepare Hematology and Oncology fellows in the OSU Divisions of Hematology and Medical Oncology for academic careers in clinical and translational cancer investigation. The rationale for this training program is based on our firm belief that progress in cancer therapy and prevention will require strong collaborative efforts, and that patient oriented physician investigators will provide a critical link with physician-scientists and basic scientists toward this goal. The OSU Comprehensive Cancer Center (OSU CCC) provides a rich research environment that fosters collaborations among multiple disciplines, yet which currently lacks a focused mentoring experience for physicians interested primarily in pursuing patient oriented cancer research. The recent explosive growth of scientific discoveries and the increasing complexity of cancer clinical trials particularly, phase I/II studie of novel therapeutic agents and regimens, make it imperative that trainees in hematology and oncology acquire the proper mentoring and training to prepare them for careers in clinical and translational investigation. This program recognizes that successful preparation of fellowship trainees for productive academic careers is dependent upon many factors including an intellectually rigorous curriculum, adequate mentoring and support from senior faculty, protected time for academic training during fellowship, "hands on" experience in developing and writing clinical studies and research papers, and adequate opportunities to enhance their OSU experience with extramural programs and workshops sponsored by the NCI or other professional academic organizations such as ASCO and ASH. The participating members consist of the Program Directors, Coordinating Committee members, Advisory Committee members, primary mentors, and contributing faculty chosen based on their prior track record of successful mentoring as well as their demonstrated commitment to clinical and translational research. This program has a proposed duration of two years and will focus on the strengths of the OSU CCC, primarily in the fields of cancer prevention and experimental therapeutics. It is designed to foster and ensure the development of fellowship trainees who will be well prepared not only to assume positions as faculty members upon graduation but who will be empowered to become independent clinical and translational investigators in their own right. Furthermore, OSU is deeply committed to training women and members of underrepresented racial and ethnic groups for academic careers, and this program will build upon our proven success in recruiting and training female and underrepresented minority fellows.